SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lucido Louis C.
(Last) (First) (Middle)
2390 EAST ORANGEWOOD AVENUE
SUITE 500
(Street)
ANAHEIM CA 92806
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BioCorRx Inc. [ BICX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President
3. Date of Earliest Transaction (Month/Day/Year)
06/28/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 06/28/2024 A(1) 10,204 A $0 588,800 D
Common Stock, par value $0.001 06/28/2024 A(2) 34,016 A $0 622,816 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. (the "Company") and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock par value $0.001 per share (the "Common Stock") equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49.
2. These shares were issued to Mr. Lucido pursuant to an Executive Service Agreement (the "Agreement"), dated January 5, 2024, by and between Company and Mr. Lucido. As compensation for his services under the Agreement, Mr. Lucido shall be issued, upon the last day of each month during the term of the Agreement, the number of shares Common Stock equivalent to $16,667 as determined based on the average closing price on the three trading days immediately preceding the last day of such month. The average closing price on the three trading days immediately preceding the date of this transaction was $0.49.
Remarks:
/s/ Louis C. Lucido 07/10/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
BioCorRx (QB) (USOTC:BICX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more BioCorRx (QB) Charts.
BioCorRx (QB) (USOTC:BICX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more BioCorRx (QB) Charts.